GLPwatch
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
Ann Intern Med · 2023
Last updated 2026-05-28In a 5-year study of 5,047 adults with type 2 diabetes, those taking glargine or liraglutide had better blood sugar control compared to those taking glimepiride or sitagliptin. The study did not report the exact percentages of improvement.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2023 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, et al. N Engl J Med. 2022;387:1063-74. 36129996.
Verbatim abstract via PubMed 36592465 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.